A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of the Bispecific T-Cell Engager MEDI-538 [MT 103, blinatumomab; Micromet, Med immune] In Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) Who Have Residual Disease Following Previous Therapy for CLL
Phase of Trial: Phase I/II
Latest Information Update: 13 Dec 2007
At a glance
- Drugs Blinatumomab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 13 Dec 2007 Micromet expects to initate this trial in the first quater of 2008.
- 13 Dec 2007 New trial record.